RIBOLIFE-B (06938) announced the appointment of Dr. Anders Gabrielsen as Chief Medical Officer. Dr. Gabrielsen will oversee the company's overall clinical development, medical affairs, and regulatory compliance. Separately, Dr. John Taylor has been appointed Chief Business Officer, responsible for the company's business development, licensing activities, and strategic investments. Dr. Gan Liming has stepped down from the role of Chief Medical Officer but will continue to serve as an Executive Director, Co-CEO, and President of Global R&D. All changes are effective March 25, 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments